Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest microarray technology Stories

2013-01-07 12:25:55

ROCKVILLE, Md., Jan. 7, 2013 /PRNewswire/ -- OriGene Technologies, Inc. ("OriGene"), one of the industry leaders in producing genome wide products for research and diagnostic applications, has brought the antibody field one step closer to identifying and developing ultra-specific monoclonal antibodies. Specificity of antibodies for research or clinical applications is of critical importance and therefore it is a "must" to demonstrate antibody specificity with high...

2008-10-01 09:00:09

Affymetrix Inc. (Nasdaq:AFFX) and Medical Prognosis Institute A/S (MPI), a leading cancer diagnostic development company based in Denmark, today announced that they have signed a Powered by Affymetrix(TM) (PbA) agreement. With this agreement, MPI gains non-exclusive access to Affymetrix microarray technology to develop and commercialize drug sensitivity prediction and prognostic products for patients with cancer. Of 179 new anti-cancer drugs tested in Phase I trials between 1976 and...